Publications (243) Norma Carmen Gutiérrez Gutiérrez publications

filter_list

2026

  1. A Multidisciplinary Approach to the Diagnosis and Management of a Mammary Myofibroblastoma in a Male with a History of Diffuse Large B-Cell Lymphoma: A Case Report

    Hematology Reports, Vol. 18, Núm. 2

  2. Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 26, Núm. 2, pp. e213-e222.e3

  3. Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53)

    British Journal of Haematology

  4. Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

    American Journal of Hematology, Vol. 101, Núm. 5, pp. 986-997

  5. Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories

    Leukemia Research, Vol. 160

  6. Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis

    Bone Marrow Transplantation

2025

  1. Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

    Journal of Clinical Oncology, Vol. 43, Núm. 24, pp. 2679-2691

  2. Correction to: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes (Nature Genetics, (2024), 56, 9, (1878-1889), 10.1038/s41588-024-01853-0)

    Nature Genetics

  3. Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma (Journal of Clinical Oncology (2025) DOI: 10.1200/JCO-24-01893)

    Journal of Clinical Oncology

  4. European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma

    HemaSphere, Vol. 9, Núm. 10

  5. Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation

    Molecular Oncology, Vol. 19, Núm. 11, pp. 3175-3192

  6. Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma

    PLoS ONE, Vol. 20, Núm. 3 March

  7. High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

    Blood, Vol. 146, Núm. 15, pp. 1747-1758

  8. High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy

    HemaSphere, Vol. 9, Núm. 4

  9. Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance

    Blood Cancer Journal, Vol. 15, Núm. 1

  10. Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experience

    Cancers, Vol. 17, Núm. 9

  11. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

    Journal of Clinical Oncology, Vol. 43, Núm. 24, pp. 2739-2751

  12. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 25, Núm. 7, pp. 494-504

  13. MYC alterations in multiple myeloma: Genetic insights and prognostic impact

    Neoplasia (United States), Vol. 66

  14. Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis

    Blood Advances, Vol. 9, Núm. 22, pp. 5814-5827